Rehan is the founding CEO of Precede Biosciences, a company focused on maximizing precision use of medicines through a powerful blood test technology.

Prior to co-founding Precede Bio, Rehan was a member of the Healthcare Executive Committee at Merck KGaA from October 2015 to March 2022, serving as the president of EMD Serono and as the chief marketing and strategy officer of Merck Healthcare. In these roles, Rehan was responsible for growing the global, multi-billion dollar specialty medicine franchises of oncology, neurology, immunology and infertility, which included leading the North American business, co-chairing the new medicine development committee (responsible for all R&D decisions from Phase 1 to approval), leading global business development, chairing global R&D alliances, and owning the launch of new medicines across the major markets.

Rehan is currently a member of the board of directors of Precede Biosciences, Tyra Biosciences, and the Massachusetts Biotechnology Council, and he holds a master’s degree in molecular and cellular biochemistry from the University of Oxford in the U.K.